The Department of Health and Human Services announced plans to update warning labels for testosterone replacement therapy products, removing longstanding restrictions and revising safety information based on the latest scientific evidence. These changes could significantly expand access to treatment for men with age-related and idiopathic hypogonadism, or low testosterone without a known underlying cause.

Why Are Federal Health Officials Changing Their Stance on Testosterone Therapy?

For years, testosterone replacement therapy has carried strict warnings about cardiovascular risks and prostate cancer. But new research is challenging those concerns. The FDA's decision follows a major clinical trial called TRAVERSE, which tracked more than 5,200 men receiving testosterone therapy. According to the study, there was no meaningful increase in the risk of major adverse cardiovascular events, including heart attack and stroke, among men receiving the treatment.

The HHS Secretary Robert F. Kennedy Jr. framed the update as a return to evidence-based medicine. "During Men's Health Month, we are putting science back at the center of men's healthcare," he stated in the announcement. "By updating testosterone therapy labels to reflect current evidence, we are giving patients and physicians clearer information, supporting informed medical decisions, and improving care for millions of American men".

Men's health experts interviewed by Healthline agreed that the risks associated with testosterone therapy have been overstated. The proposed changes focus on three major areas that directly affect how doctors can prescribe treatment and which men might benefit from it.

What Specific Changes Are Being Made to Testosterone Therapy Labels?

The FDA is proposing updates across three key areas of concern that have historically limited access to testosterone replacement therapy:

• Age-Related Hypogonadism: The FDA wants to remove a 2015 limitation stating that testosterone therapy's safety and effectiveness have not been established in men with age-related hypogonadism, the gradual decline in testosterone that occurs with aging rather than from a specific medical condition.
• Prostate Cancer Risk: Current labeling warns that testosterone therapy should not be used in men with known or suspected prostate cancer and may increase cancer risk. Under proposed changes, testosterone would only be contraindicated in men with metastatic prostate cancer, meaning cancer that has spread to other parts of the body.
• Benign Prostatic Hyperplasia: The FDA is revising warnings about benign prostatic hyperplasia, commonly known as an enlarged prostate, to reflect current safety information based on updated evidence.

These changes represent a significant shift from the cautious approach that has dominated testosterone therapy prescribing for the past decade. The April FDA announcement also encouraged manufacturers to explore a new indication for low libido in men with idiopathic hypogonadism, further expanding potential treatment options.

Is Testosterone Therapy Actually Safe for the Heart?

One of the biggest concerns driving previous restrictions was cardiovascular risk. The TRAVERSE trial, which involved more than 5,200 male participants, directly addressed this worry. The study found no meaningful increase in major adverse cardiovascular events among men receiving testosterone replacement therapy when properly monitored.

"Even before this trial had been conducted, it was well known in the men's health community that testosterone replacement within physiologic ranges is safe and should not cause adverse cardiovascular events. This study reinforces this common knowledge," said S. Adam Ramin, a board certified urologist and urologic oncologist.

S. Adam Ramin, MD, Board Certified Urologist and Medical Director of Urology Cancer Specialists

However, experts emphasize that safety depends heavily on maintaining testosterone levels within the normal physiologic range. Ramin noted that clinicians should generally target testosterone levels between approximately 350 and 750 ng/dL (nanograms per deciliter, a standard measurement of hormone concentration in blood). Super physiologic levels substantially above that range may increase red blood cell production and potentially raise the risk of blood clots, heart attack, or stroke.

Does Testosterone Therapy Actually Cause Prostate Cancer?

Perhaps the most significant change involves prostate cancer warnings. The current labeling generally discourages testosterone therapy in men with any prostate cancer concern and warns that treatment may increase cancer risk. But experts say this concern is not supported by evidence.

"There is no evidence that TRT promotes prostate cancer," stated Franck Mauvais-Jarvis, a professor of medicine at Tulane University and director of the VA hormone therapy clinic at New Orleans Medical Center.

Franck Mauvais-Jarvis, MD, PhD, Professor of Medicine at Tulane University

According to the HHS, available clinical trial and epidemiologic evidence have not generally shown an increased risk of prostate cancer among men receiving testosterone replacement therapy. However, officials acknowledge that some uncertainty exists because prostate cancer can take years to develop.

Ramin emphasized an important distinction: testosterone may accelerate growth of an already existing prostate cancer, but that differs fundamentally from causing cancer to develop in the first place. He noted that some men with a history of treated prostate cancer who have remained disease-free for more than two years, as well as certain men with low-grade, dormant prostate cancers, may be considered for testosterone therapy in selected circumstances.

How to Approach Testosterone Therapy Safely

• Get Proper Screening First: Before starting testosterone replacement therapy, work with your doctor to assess prostate cancer risk through appropriate screening and monitoring, which experts describe as an important component of safe treatment.
• Maintain Physiologic Levels: Ensure your healthcare provider targets testosterone levels between approximately 350 and 750 ng/dL rather than super physiologic levels, which may increase risks of blood clots and cardiovascular events.
• Monitor Regularly: Testosterone replacement therapy requires ongoing monitoring to ensure treatment effectiveness and safety, with regular follow-up appointments to check hormone levels and overall health status.

The proposed label changes represent a significant evolution in how federal health officials view testosterone replacement therapy. Rather than viewing it as inherently risky, the updated approach emphasizes appropriate patient selection, proper dosing, and regular monitoring as the keys to safe and effective treatment.